TY - JOUR
T1 - Immunogenicity and protection against mycobacterium caprae challenge in goats vaccinated with BCG and revaccinated after one year
AU - Arrieta-Villegas, Claudia
AU - Vidal, Enric
AU - Martín, Maite
AU - Verdés, Judit
AU - Moll, Xavier
AU - Espada, Yvonne
AU - Singh, Mahavir
AU - Villarreal-Ramos, Bernardo
AU - Domingo, Mariano
AU - de Val, Bernat Pérez
N1 - Funding Information:
Funding: This work was funded by a grant from Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), reference number RTA2015-00043-C02-01 (FEDER co-funded). IRTA is supported by CERCA Programme/Generalitat de Catalunya. Claudia Arrieta-Villegas is the recipient of a predoctoral fellowship from INIA (INIA-FPI, grant No. CPD2016-0109).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/12/10
Y1 - 2020/12/10
N2 - Vaccination has been proposed as a supplementary tool for the control of tuberculosis in livestock. The long-term immunogenicity elicited by bacillus Calmette–Guerin (BCG) and the efficacy of revaccination were investigated in thirty goat kids distributed into three groups: unvaccinated controls, BCG (vaccinated at week 0) and BCG-BCG (vaccinated at weeks 0 and 56). Sixty-four weeks after the first vaccination, all animals were challenged with Mycobacterium caprae and examined post-mortem (pathology and bacterial load) at week 73. Antigen-specific interferon-gamma (IFN-γ) release was measured throughout the experiment. At week 59, peripheral blood mononuclear cells were stained for CD4, CD45RO and IFN-γ to determine the presence of antigen-specific cells secreting IFN-γ. The BCG-BCG group showed reductions in rectal temperatures, M. caprae DNA load in pulmonary lymph nodes (LN), the volume of lesions in pulmonary LN, mineralization in lungs, and higher weight gains compared to unvaccinated controls. IFN-γ responses were undetectable from 32 weeks after primary vaccination until revaccination, when the BCG-BCG group showed detectable IFN-γ production and a greater percentage of antigen-specific CD4+CD45RO+IFNγ+ and CD4−CD45RO+IFNγ+ cells compared to the BCG and control groups, which may be an indicator of the mechanisms of protection. Thus, re-vaccination of goats with BCG appears to prolong protection against infection with M. caprae.
AB - Vaccination has been proposed as a supplementary tool for the control of tuberculosis in livestock. The long-term immunogenicity elicited by bacillus Calmette–Guerin (BCG) and the efficacy of revaccination were investigated in thirty goat kids distributed into three groups: unvaccinated controls, BCG (vaccinated at week 0) and BCG-BCG (vaccinated at weeks 0 and 56). Sixty-four weeks after the first vaccination, all animals were challenged with Mycobacterium caprae and examined post-mortem (pathology and bacterial load) at week 73. Antigen-specific interferon-gamma (IFN-γ) release was measured throughout the experiment. At week 59, peripheral blood mononuclear cells were stained for CD4, CD45RO and IFN-γ to determine the presence of antigen-specific cells secreting IFN-γ. The BCG-BCG group showed reductions in rectal temperatures, M. caprae DNA load in pulmonary lymph nodes (LN), the volume of lesions in pulmonary LN, mineralization in lungs, and higher weight gains compared to unvaccinated controls. IFN-γ responses were undetectable from 32 weeks after primary vaccination until revaccination, when the BCG-BCG group showed detectable IFN-γ production and a greater percentage of antigen-specific CD4+CD45RO+IFNγ+ and CD4−CD45RO+IFNγ+ cells compared to the BCG and control groups, which may be an indicator of the mechanisms of protection. Thus, re-vaccination of goats with BCG appears to prolong protection against infection with M. caprae.
KW - Antigen-specific memory T-cells
KW - BCG
KW - Diagnosis
KW - Duration of immunity
KW - Goat
KW - Interferon gamma
KW - Revaccination
KW - Tuberculosis
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85097940824&partnerID=8YFLogxK
U2 - 10.3390/vaccines8040751
DO - 10.3390/vaccines8040751
M3 - Article
C2 - 33322064
AN - SCOPUS:85097940824
SN - 2076-393X
VL - 8
JO - Vaccines
JF - Vaccines
IS - 4
M1 - 751
ER -